Biologic therapy in familial Mediterranean fever

References

• Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351(9103):659–64.
   PubMed Web of Science ®Google Scholar
• Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxf). 2004;43(4):410–15.
   PubMed Web of Science ®Google Scholar
• Federici S, Sormani M.P, Ozen S, Lachmann H.J, Amaryan G, Woo P, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74(5):799–805.
   PubMed Web of Science ®Google Scholar
• Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43(3):387–91.
   PubMed Web of Science ®Google Scholar
• Majeed HA and Barakat M. Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr. 1989;148(7):636–41.
   PubMed Web of Science ®Google Scholar
• Zemer D, Livneh A, Danon YL, Pras M, and Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34(8):973–7.
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Aamar S. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol. 2009;27(2 Suppl 53):S1–3.
   Google Scholar
• Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med. 2004;200(5):551–8.
   PubMed Web of Science ®Google Scholar
• Kim ML, Chae JJ, Park YH, De Nardo D, Stirzaker RA, Ko HJ, et al. Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J Exp Med. 2015;212(6):927–38.
   PubMed Web of Science ®Google Scholar
• Hoffman HM. Therapy of autoinflammatory syndromes. J Allergy Clin Immunol. 2009;124(6):1129–38. quiz 39-40.
   PubMed Web of Science ®Google Scholar
• Bagci S, Toy B, Tuzun A, Ates Y, Aslan M, Inal A, et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol. 2004;23(4):333–7.
   PubMed Web of Science ®Google Scholar
• Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S77–86.
   Web of Science ®Google Scholar
• Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine. 2008;75(4):504–5.
   PubMed Web of Science ®Google Scholar
• Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci. 2013;346(2):137–41.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Migita K, Tsukada T, Umeda M, Nonaka F, Kawakami A, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl 77):150–1.
   PubMed Web of Science ®Google Scholar
• Hamanoue S, Suwabe T, Hoshino J, Sumida K, Mise K, Hayami N, et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2015;25:1–4.
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Cinar M, Simsek I, Erdem H, Pay S. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2015;54(3):564–5.
   PubMed Web of Science ®Google Scholar
• Umeda M, Aramaki T, Fujikawa K, Iwamoto N, Ichinose K, Terada K, et al. Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis. Int J Rheum Dis. 2015. [Epub ahead of print] doi:10.1111/1756-185X.12776.
   Google Scholar
• Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314(2):363–9.
   PubMed Web of Science ®Google Scholar
• Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity. 2011;34(5):755–68.
   PubMed Web of Science ®Google Scholar
• Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA. 2006;103(26):9982–7.
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14(9):1590–604.
   PubMed Web of Science ®Google Scholar
• Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A. Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis. 2014;73(2):462–9.
   PubMed Web of Science ®Google Scholar
• Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–18.
   PubMed Web of Science ®Google Scholar
• Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146(11):825–6.
   PubMed Web of Science ®Google Scholar
• Gattringer R, Lagler H, Gattringer KB, Knapp S, Burgmann H, Winkler S, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest. 2007;37(11):912–14.
   PubMed Web of Science ®Google Scholar
• Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007;66(11):1545–6.
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Papadopoulos VP, Konstantinidis T, and Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med. 2008;66(11):489–91.
   PubMed Web of Science ®Google Scholar
• Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24(2):676–8.
   PubMed Web of Science ®Google Scholar
• Bilginer Y, Ayaz N.A, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29(2):209–10.
   PubMed Web of Science ®Google Scholar
• Meinzer U, Quartier P, Alexandra J.F, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265–71.
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70(7):1347–8.
   PubMed Web of Science ®Google Scholar
• Alpay N, Sumnu A, Caliskan Y, Yazici H, Turkmen A, Gul A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2012;32(10):3277–9.
   PubMed Web of Science ®Google Scholar
• Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898–901.
   PubMed Web of Science ®Google Scholar
• Celebi ZK, Kucuksahin O, Sengul S, Tuzuner A, Keven K. Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra. Clin Kidney J. 2014;7(2):219–20.
   PubMedGoogle Scholar
• Basaran O, Uncu N, Celikel BA, Taktak A, Gur G, Cakar N. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015;25(4):621–4.
   PubMed Web of Science ®Google Scholar
• Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation. 2015;38(1):27–31.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533–41.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Huang B. The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF. Isr Med Assoc J. 2015;17(3):137–40.
   PubMed Web of Science ®Google Scholar
• Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol. 2009;183(2):792–6.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2(8657):244–7.
   PubMed Web of Science ®Google Scholar
• Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol. 1995;25(6):1794–7.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S99–103.
   Google Scholar
• Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24(4):435–7.
   PubMed Web of Science ®Google Scholar
• Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol. 2007;13(1):38–40.
   PubMed Web of Science ®Google Scholar
• Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol. 2011;21(6):684–90.
   PubMed Web of Science ®Google Scholar
• Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17(7):358–62.
   PubMed Web of Science ®Google Scholar
• Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005;53(1):146–7.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Matsuda M, Tazawa K, Shimojima Y, Ikeda S. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med. 2007;46(15):1247–9.
   PubMed Web of Science ®Google Scholar
• Kosmidou M, Mpolotsis V, Christou L, Tsianos E.V. Late onset of Crohn’s disease in familial Mediterranean fever: the necessity of anti-TNF treatment. J Dig Dis. 2014;15(2):102–4.
   PubMed Web of Science ®Google Scholar
• Erten S, Erten SF, Altunoglu A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int. 2012;32(4):1095–7.
   PubMed Web of Science ®Google Scholar
• Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004;10(3):134–7.
   PubMed Web of Science ®Google Scholar
• Ozcakar ZB, Yuksel S, Ekim M, Yalcinkaya F. Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol. 2012;31(8):1267–71.
   PubMed Web of Science ®Google Scholar
• Yuksel S, Yalcinkaya F, Acar B, Ozcakar Z.B, Ozturk B, Ekim M. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2006;45(10):1307–8.
   PubMed Web of Science ®Google Scholar
• Kaya S, Kaptanoglu E, Elden H, Hizmetli S. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med. 2010;49(6):619–22.
   PubMed Web of Science ®Google Scholar
• Bonyadi M, Bahrami S, Jahanafrooz Z, Dastgiri S. Tumor necrosis factor-α gene polymorphisms in FMF and their association with amyloidosis . Clin Appl Thromb Hemost. 2012;18(6):633–7.
   PubMed Web of Science ®Google Scholar
• Cosan F, Ustek D, Oku B, Duymaz-Tozkir J, Cakiris A, Abaci N, et al. Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. Arthritis Rheum. 2010;62(11):3232–6.
   PubMed Web of Science ®Google Scholar
• Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–83.
   PubMed Web of Science ®Google Scholar
• Rabinovich E, Livneh A, Langevitz P, Brezniak N, Shinar E, Pras M, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis. 2005;64(7):1009–14.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46(3):755–65.
   PubMed Web of Science ®Google Scholar
• Lipsky P.E. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006;8(Suppl 2):S4.
   Web of Science ®Google Scholar
• Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2008;2(1):75–82.
   PubMedGoogle Scholar
• Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, et al. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 2014;24(3):405–9.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137–43.
   PubMed Web of Science ®Google Scholar